|
Alveolar Soft Part Sarcoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Alveolar soft-part sarcoma (ASPS) is a rare neoplasm with chromosomal translocation that results in ASPL-TFE3 fusion.
|
18714394 |
2008 |
|
Alveolar Soft Part Sarcoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Alveolar soft part sarcoma (ASPS), a deadly soft tissue malignancy with a predilection for adolescents and young adults, associates consistently with t(X;17) translocations that generate the fusion gene ASPSCR1-TFE3.
|
25453902 |
2014 |
|
Alveolar Soft Part Sarcoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Alveolar soft part sarcoma (ASPS) is a rare mesenchymal tumor characterized by ASPL-TFE3 translocation.
|
29350467 |
2018 |
|
Alveolar Soft Part Sarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Alveolar soft-part sarcoma (ASPS) is a morphologically distinctive mesenchymal tumor characterized by a canonical ASPL-TFE3 fusion product.
|
30018044 |
2018 |
|
Alveolar Soft Part Sarcoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Alveolar soft part sarcoma (ASPS) is a rare malignancy with high rates of metastasis at presentation, defined by an unclear cellular origin and a unique unbalanced ASPSCR1-TFE3 translocation (der(17)t(X:17)(p11:q25)).<sup>1</sup> ASPS is insensitive to chemotherapy and has been reported to involve the bladder only twice in the pediatric literature; once as a primary malignancy,<sup>2</sup> and once as a secondary malignancy after cytotoxic chemotherapy.<sup>3</sup> Herein, we report the third case of pediatric bladder ASPS in a female patient who received cytotoxic chemotherapy for low-risk neuroblastoma.
|
30986487 |
2019 |
|
Alveolar Soft Part Sarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
TFE3 staining and knowledge of its microscopic characteristics would facilitate earlier diagnosis: Early diagnosis with a multidisciplinary, multimodal approach to treatment is required to achieve extended disease-free survival in patients with brain metastatic ASPS.
|
29113207 |
2017 |
|
Alveolar Soft Part Sarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
TFE3 fluorescence in situ hybridization was positive in all tested ASPS and Xp11-RCC.
|
30851332 |
2019 |
|
Alveolar Soft Part Sarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
TFE3 regulates both Golgi and lysosomal homeostasis and is rearranged in renal cell carcinoma (RCC), alveolar soft part sarcoma, epithelioid hemangioendothelioma, and perivascular epitheloid cell tumors (PEComas).
|
31774608 |
2020 |
|
Alveolar Soft Part Sarcoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Transcription factor E3 (TFE3) is a useful marker for tumors with Xp11.2 translocation, including alveolar soft part sarcoma and renal cell carcinoma.
|
31788112 |
2019 |
|
Alveolar Soft Part Sarcoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A relationship between these renal tumors and ASPS was initially suggested by the cytogenetic finding of a balanced t(X;17)(p11.2;q25) in two of the cases, and the ASPL-TFE3 fusion transcripts were then confirmed by reverse transcriptase-polymerase chain reaction.
|
11438465 |
2001 |
|
Alveolar Soft Part Sarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
According to European Organization for Research and Treatment of Cancer (EORTC) efficacy criteria for soft tissue sarcoma, our study demonstrated that crizotinib has activity in TFE3 rearranged ASPS MET+ patients.
|
29216400 |
2018 |
|
Alveolar Soft Part Sarcoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
All conventional sections from the Xp11.2 RCC and alveolar soft part sarcoma cases were positive for the TFE3 rearrangement by FISH.All remaining cases were negative.
|
21817901 |
2011 |
|
Alveolar Soft Part Sarcoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
ASPSCR1-TFE3 fusion transcripts were identified in 16 of 18 ASPS samples.
|
18094412 |
2007 |
|
Alveolar Soft Part Sarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
At the molecular level RT-PCR and sequencing analysis demonstrated ASPCR1-TFE3 fusion confirming the histological diagnosis of ASPS.
|
18713311 |
2009 |
|
Alveolar Soft Part Sarcoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Both Xp11.2 translocation renal cell carcinoma (RCC) and alveolar soft part sarcoma (ASPS) are characterized by various translocations disrupting chromosome Xp11.2, which result in gene fusions involving the TFE3 transcription factor gene.
|
20421778 |
2010 |
|
Alveolar Soft Part Sarcoma
|
0.400 |
FusionGene
|
disease |
ORPHANET |
Detection of ASPL/TFE3 fusion transcripts and the TFE3 antigen in formalin-fixed, paraffin-embedded tissue in a series of 18 cases of alveolar soft part sarcoma: useful diagnostic tools in cases with unusual histological features.
|
21279521 |
2011 |
|
Alveolar Soft Part Sarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Eleven cases with an initial diagnosis of ASPS at female genital tract sites were evaluated for their morphologic features and immunoprofile using a panel of antibodies (TFE3, HMB45, melan-A, smooth muscle actin, desmin, and h-Caldesmon).
|
28009610 |
2017 |
|
Alveolar Soft Part Sarcoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Following identification of an index case of ASPS with a novel TFE3 fusion partner, we performed a retrospective review to determine whether this represents an isolated event.
|
31433528 |
2019 |
|
Alveolar Soft Part Sarcoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, among neoplasms with the SFPQ-TFE3, NONO-TFE3, DVL2-TFE3, and ASPL-TFE3 gene fusions, the RCCs are almost always PAX8 positive, cathepsin K negative by immunohistochemistry, whereas the mesenchymal counterparts (Xp11 translocation PEComas, melanotic Xp11 translocation renal cancers, and alveolar soft part sarcoma) are PAX8 negative, cathepsin K positive.
|
26975036 |
2016 |
|
Alveolar Soft Part Sarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Given that the two derivative chromosomes of a translocation in G2 would be expected to segregate together half the time, the predominance of an unbalanced der(17)t(X;17) also raises the possibility of a selective advantage in ASPS cells for gain of Xp11.2-->pter or loss of 17q25.3-->qter or retention of an active copy of TFE3.
|
15952162 |
2005 |
|
Alveolar Soft Part Sarcoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Here, we report the first systematic study applying TFE3 immunoassay and ASPL-TFE3 fusion transcript detection to archival paraffin-embedded tissues in a large Chinese ASPS patient population.
|
18382356 |
2008 |
|
Alveolar Soft Part Sarcoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical discrimination between the ASPL-TFE3 fusion proteins of alveolar soft part sarcoma.
|
18176180 |
2008 |
|
Alveolar Soft Part Sarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Immunostaining showed that all Xp11.2 RCC and ASPS cases had strong TFE3 expression and high positive ratios for p53 and vimentin.
|
24427344 |
2014 |
|
Alveolar Soft Part Sarcoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Integration of these data with expression profiles of ASPS tumour samples and inducible cell lines expressing ASPSCR1-TFE3 defined a subset of 332 genes as putative up-regulated direct targets of ASPSCR1-TFE3, including MET (a previously known target gene) and 64 genes as down-regulated targets of ASPSCR1-TFE3.
|
23288701 |
2013 |
|
Alveolar Soft Part Sarcoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
It is characterized by a specific chromosomal alteration, der(17)t(X:17)(p11:q25), resulting in fusion of the transcription factor E3 (TFE3) with alveolar soft part sarcoma critical region 1 (ASPSCR1) at 17q25.
|
26516944 |
2015 |